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Lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC)
are two distinct and predominant types of human lung cancer. IκB
kinase α (IKKα) has been shown to suppress lung SCC develop-
ment, but its role in ADC is unknown. We found inactivating mu-
tations and homologous or hemizygous deletions in the CHUK
locus, which encodes IKKα, in human lung ADCs. The CHUK dele-
tions significantly reduced the survival time of patients with lung
ADCs harboring KRAS mutations. In mice, lung-specific Ikkα abla-
tion (IkkαΔLu) induces spontaneous ADCs and promotes KrasG12D
-initiated ADC development, accompanied by increased cell prolifer-
ation, decreased cell senescence, and reactive oxygen species (ROS)
accumulation. IKKα deletion up-regulates NOX2 and down-
regulates NRF2, leading to ROS accumulation and blockade of cell
senescence induction, which together accelerate ADC development.
Pharmacologic inhibition of NADPH oxidase or ROS impairs KrasG12D-
mediated ADC development in IkkαΔLu mice. Therefore, IKKα modu-
lates lung ADC development by controlling redox regulatory
pathways. This study demonstrates that IKKα functions as a suppres-
sor of lung ADC in human andmice through a uniquemechanism that
regulates tumor cell-associated ROS metabolism.
lung adenocarcinoma | IKKα | ROS | cell senescence | tumor progression
Multiple somatic aberrations in human cancer challenge ourunderstanding of the mechanisms underlying cancer initi-
ation, progression, and metastasis (1, 2). Alterations in second-
ary tumor drivers and modifiers can diversify signaling pathways,
which modulate cancer cell fate as well as therapeutic efficacy.
Human lung cancer is the leading cause of cancer-related mor-
tality (3). Human lung cancer is classified into small cell lung
cancer (∼15%) and non-small cell lung cancer (NSCLC; ∼85%).
Lung squamous cell carcinoma (SCC; 25%) and adenocarci-
noma (ADC; 65%) are the main types of NSCLC. Due to a
decline in the smoking population, lung ADC has emerged as the
predominant lung malignancy in humans. ADC is frequently
located in the lower lobes of the lungs or peripheral lung tissues
and is derived from type I and II lung epithelial cells (4). SCC is
located in the upper lungs and is derived from the basal cells of
the bronchial epithelium, and it specifically expresses keratin 5
(K5) and K14 basal cell markers (5). Understanding how these
different cancer-associated genetic alterations regulate lung tu-
morigenesis is important for the design of rational treatments.
Human cancer genome sequencing identifies activating KRAS
mutations in ∼35% of lung ADC and 5% of lung SCC, and
mutations of the gene encoding Kelch-like ECH-associated
protein 1 (KEAP1), an E3 ubiquitin ligase that induces degra-
dation of nuclear factor (erythroid-derived 2)-like 2 (NRF2), in
18% and 12% of lung ADC and SCC, respectively (1, 2). KEAP1
mutations can result in NRF2 accumulation and antioxidant
responses (6). In addition, oncogenic Kras and Myc induce
NRF2 expression, and the PI3K-AKT signaling activates NRF2
(7). The increased NRF2 exerts its oncogenic potential by en-
hancing AP-1 and Adam10/EGFR activities and protecting cancer
cells from reactive oxygen species (ROS)-induced death (8–10).
The IκB kinase (IKK) complex, composed of IKKα, IKKβ,
and NEMO (IKKγ), is essential for the activation of NF-κB
and other important cellular functions (11). IKKα regulates
canonical and noncanonical NF-κB signaling as well as NF-
κB–independent functions (12–15). KEAP1 also regulates
turnover of IKKβ, but not of IKKα or NEMO (16). NF-κB
activity is required for Kras-initiated lung ADC development
because it supports cell survival (17), and an absence of IKKβ
attenuates Kras-induced ADC development (18). We have
previously shown that lung IKKα inactivation induces spon-
taneous SCC development in mice, associated with increased
lung inflammation (5); however, the role of IKKα in lung
ADC is unclear.
Significance
Reactive oxygen species (ROS) can promote tumorigenesis or
kill cancer cells. How different cancer-associated genetic alter-
ations regulate ROS balance and outcome is of great impor-
tance for the design of rational cancer treatments, many of
which affect ROS metabolism and sensing. Kras activation in-
duces a ROS defense system and cell senescence, which coun-
teract its oncogenic activity. KRAS-activating mutations are
accompanied by IKKα loss mutations that result in elevated
NOX2 but decreased expression of the NRF2 ROS defense sys-
tem. Thus, IKKα ablation turns the antitumorigenic effect of
Kras-induced ROS to a protumorigenic effect that enhances Kras-
induced progression of lung adenocarcinoma (ADC). Restoration
of IKKα activity or inhibition of the pathways activated on its loss
may offer new opportunities for ADC treatment.
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ROS are essential for maintaining cellular metabolism, sur-
vival, proliferation, and differentiation in normal cells. Cancer
cells adapt to exist with elevated ROS levels compared with
normal cells (19, 20). Numerous studies have documented that
excessive ROS either promote tumor development or kill cancer
cells via an apoptotic mechanism (21, 22). In response to ROS,
NRF2 up-regulates the expression of antioxidants and de-
toxifying enzymes, thereby maintaining ROS homeostasis. NRF2
has been shown to inhibit KrasG12D-initiated early lung ADC
but to accelerate advanced ADC (23); however, most human
lung ADCs do not harbor KEAP1 mutations that result in NRF2
accumulation (1, 24). Thus, there remains a need to identify
additional NRF2 regulators and mechanisms underlying NRF2
accumulation or down-regulation in lung ADC.
Chemical carcinogens induce activating Hras mutations and
ROS accumulation in mouse skin (25, 26). Deletion of NRF2 or
NAD(P)H quinone dehydrogenase 1 (NQO1, an NRF2 target)
enhances carcinogen-induced skin carcinogenesis in mice (27,
28). Ikka+/− mice develop many more skin papillomas and ma-
lignant carcinomas than wild-type (WT) mice in response to
carcinogen administration (26). Given the known activities of
NRF2 and NQO1 in scavenging ROS, these phenotypic simi-
larities among NRF2, NQO1, and IKKα suggest that all may
impact ROS accumulation and Hras activation during skin tu-
morigenesis. To date, the regulatory relationship between NRF2
and IKKα remains unclear. Moreover, activated Kras promotes
ROS accumulation, which induces cell senescence (29–31), an-
tagonizing Kras-initiated lung ADC progression. How NRF2
regulates the antitumorigenic effects of Kras-induced ROS
merits further investigation.
The Cancer Genome Atlas (TCGA) database analysis has
revealed the mutations and deletions in the CHUK locus, which
encodes IKKα, in a subfraction of human lung ADC. Here we
show that lung-specific IKKα ablation induces spontaneous lung
ADC and promotes Kras-initiated lung ADC development in
mice, and further demonstrate that IKKα controls ADC devel-
opment through its unique effects on ROS metabolism, medi-
ated through NRF2 and NOX2.
Results
Lung Epithelial Cell IKKα Suppresses ADC Development. To in-
vestigate the effect of IKKα on lung ADC development, we
ablated IKKα in lungs of C57BL/6 Ikkαf/f mice (15) by intra-
tracheal Adenovirus.Cre (Ad.Cre) administration (IkkαΔLu).
Conditional deletion of IKKα resulted in spontaneous lung
ADCs in 8 out of 48 IkkαΔLu mice at 13–20 mo of age (Fig. 1A,
Top). No lung ADCs were detected in 30 WT mice. Activating
KRAS mutations at amino acid 12 are commonly identified in
human lung ADC (1), and KrasG12D activation induces sponta-
neous lung ADC in mice (32). Thus, ADC developed from
C57BL/6 KrasLSL-G12D (KrasG12D) mice were used as positive
controls (Fig. 1A, Bottom). With increasing age, ADC derived
from IkkαΔLu mice metastasized to the spleen and other organs,
as indicated by positivity for SP-C, a marker of type II lung ep-
ithelial cells (Fig. S1A).
To investigate the effect of IKKα on KrasG12D-induced lung
ADC, we crossed C57BL/6 Ikkαf/f mice or IkkαKA/KA mice with
C57BL/6 KrasG12D mice and used Ad.Cre to induce KrasG12D
expression and simultaneously delete IKKα. KrasG12D;IkkαΔLu
and KrasG12D;IkkaKA/KA mice showed a significantly greater lung
tumor burden compared with KrasG12D mice (Fig. 1 B and C and
Fig. S1B). ADCs derived from KrasG12D, KrasG12D;IkkαΔLu, and
KrasG12D;IkkαKA/KA mice were positive for SP-C and CC10 (a
marker of lung epithelial Clara cells), but negative for K5, an
SCC marker (Fig. 1 D and E). We confirmed Ikkα deletion and
KrasG12D activation in KrasG12D;IkkαΔLu lung ADCs and
KrasG12D activation in KrasG12D;IkkaKA/KA ADCs (Fig. S1C).
Following Ad.Cre treatment, KrasG12D;Ikkαf/f, KrasG12D;Ikkαf/+,
and KrasG12D;Ikkα+/− mice showed a significantly reduced life
span compared with KrasG12D mice (Fig. 1F and Fig. S1D). Loss
of the WT Ikkα allele [i.e., loss of heterozygosity (LOH), a tu-
mor- suppressor hallmark] was detected in KrasG12D;Ikkα+/− lung
ADCs (Fig. S1E). Ikkα LOH was previously reported in
carcinogen-induced skin tumors in Ikkα+/− mice (26). Collec-
tively, these results indicate that lung epithelial cell IKKα abla-
tion promotes KrasG12D-initiated lung ADC development.
Although FVB L-IkkαKA/KA mice, in which lysine is replaced by
alanine at amino acid 44 of IKKα, develop spontaneous lung
SCC (5), we did not detect lung SCC in FVB or C57BL/6
IkkαΔLu mice, KrasG12D;IkkαΔLu mice, or KrasG12D;IkkaKA/KA
mice in this study.
We then examined the TCGA database (cBioPortal) of Hu-
man Cancer Genomics (1) and found a 2.2% mutation rate in the
CHUK locus in lung ADC, including CHUKX411 and CHUKE53
point mutations, which generate the C-terminal truncated IKKα
variants lacking its leucine zipper (LZ) and helix-loop-helix
(HLH) domains, as well as CHUK homozygous deletions (Fig.
1G, Top). We also found CHUK hemizygous deletions in ∼22%
of human lung ADCs (Fig. 1G, Bottom). The LZ and HLH
motifs are required for IKKα activity (13, 15, 33, 34). Human
lung ADCs carrying CHUK mutations had an activating KRAS
mutation that causes an amino acid change at position 12, as
well as TP53 mutations (Fig. 1G, Top and Fig. S1F). Eight out
of 51 human lung ADCs bearing a CHUK hemizygous deletion
also had an activating KRAS G12C or G12V mutation (Fig.
1G, Bottom), suggesting that some CHUK alterations have a
positive correlation with activating KRAS mutations.
We also examined the effect of CHUK mutations on the
survival of patients with lung ADC. The median survival of
the patients in this cohort is 44.6 mo (1), compared with
19.5 mo for patients with CHUK mutations and 35.5 mo for
patients with KRAS mutations. Although the number of pa-
tients with a CHUK mutation is limited, the data suggest that
patients with lung ADC with CHUK mutations may have a
tendency toward shorter survival. We further compared the
survival curves among patients with CHUK alterations, in-
cluding mutations and hemizygous deletions, KRAS muta-
tions, and KRAS mutations/CHUK hemizygous deletions, and
found that CHUK mutations or hemizygous deletions signif-
icantly reduced the survival time of patients with lung ADC
carrying a KRAS mutation (Fig. 1H). Based on the foregoing
animal results, IKKα inactivation may promote human lung
ADC development.
Reduced IKKα Promotes Bronchial Epithelial Cell Proliferation and
Attenuates Cell Senescence. Compared with KrasG12D mice,
KrasG12D;IkkαΔLu and KrasG12D;IkkaKA/KA mice developed sig-
nificantly enlarged lungs with markedly increased Ki67-positive
bronchial epithelial cells, which can give rise to lung ADCs (Fig. 2
A and B and Fig. S2A), suggesting that IKKα reduction or deletion
promotes lung epithelial cell proliferation. The IkkαKA mutation
severely destabilizes IKKα and also abolishes its catalytic activity (5).
Indeed, IKKα levels were decreased in KrasG12D;IkkaKA/KA lung
ADCs compared with WT lungs and KrasG12D ADCs (Fig. S2B).
Moreover, following intratracheal treatment with Ad.Cre, a
small group of KrasG12D;IkkaKA/KA mice developed severe skin
lesions, precluding their maintenance. Thus, we used Ikkaf/f mice
for all subsequent studies.
Oncogenic KrasG12D induces premalignant lesions by in-
creasing cell senescence, as indicated by senescence-associated
β-galactosidase (SA-β-gal) staining (30). KrasG12D;IkkαΔLu lung
ADCs displayed substantially less SA-β-gal staining and more
Ki67 than KrasG12D ADCs (Fig. 2C and Fig. S2C). The tumor
suppressor p53 is essential for induction of cell senescence (30).
Decreased p53 and p21Cip1 (p21) expression can overcome cell
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Fig. 1. IKKα deletion induces spontaneous lung ADCs and promotes Kras-initiated lung ADCs, and somatic CHUK aberrations are detected in human lung
ADCs. (A, Top) Lung-specific IKKα ablation by intratracheal Ad.Cre injection induced spontaneous lung ADCs in 8 of 48 IkkαΔLu mice and in 0 of 30 WT mice.
ADCs stained with hematoxylin and eosin (H&E) in IkkαΔLu mice at age 13 mo. (A, Bottom) H&E-stained ADCs from KrasG12D mice served as a positive control.
(Scale bar: 30 μm.) All images in this study were captured by a Nikon (Ver. 3.06) microscope. (B) Lung ADC burden in KrasG12D and KrasG12D;IkkαΔLu mice at
4 mo after Ad.Cre treatment (n = 6 mice/group) and a representative H&E-stained ADC. ***P < 0.001, Student’s t test. (Scale bar: 25 μm.) (C) Lung ADC
burden in KrasG12D and KrasG12D;IkkαKA/KA mice at 4.5 mo after Ad.Cre treatment (n = 4 mice/group) and a representative H&E-stained ADC. **P < 0.01,
Student’s t test. (Scale bar: 25 μm.) (D) Immunofluorescence (IF) staining with anti–SP-C or anti–CC10 antibody showing the tissue origins of ADCs in
KrasG12D, KrasG12D;IkkαΔLu, and KrasG12D;IkkαKA/KAmice andWT lungs (n = 3 mice/group). DAPI, nuclear staining. (Scale bar: 30 μm.) (E) ADCs from KrasG12D;IkkαΔLu
mice were stained by immunohistochemistry (IHC) with K5 or SP-C antibody (n = 3). (Scale bar: 30 μm.) (F) Survival of KrasG12D mice compared with several IKKα
mutants crossed with KrasG12D mice. **P < 0.01; *P < 0.05, Mantel–Cox log-rank test. Mouse numbers and P values are shown. The red asterisk indicates IKKα
reduction; the red #, LOH. (G, Top) CHUK mutations and deletion were found in 230 human lung ADCs (cBioPortal for Cancer Genomics) (1) that generate
truncated IKKα proteins labeled with red numbers. aa, amino acid; HLH, helix-loop-helix; KD, kinase domain; LZ, leucine zipper. (G, Bottom) Analysis of CHUK
(IKKα) mRNA expression (RNA sequence V2 RSEM) in 230 human lung ADCs (1). Putative copy number calls on 230 cases were determined using GISTIC 2.0.
Values: −2, homozygous deletion; −1, hemizygous (shallow) deletion; 0, neutral/no change; 1, gain; 2, high-level amplification. (H) Survival curves for patients with
CHUK alterations, including mutations (M) and hemizygous deletions (Hem), KRAS mutations, and KRAS mutations/CHUK hemizygous deletions. **P < 0.01,
χ2 test (comparisons between two groups).
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cycle arrest and senescence and thereby promote tumor pro-
gression. Immunoblot (IB) analysis showed lower expression of
p53 and p21 in KrasG12D;IkkαΔLu tumors than in KrasG12D tu-
mors (Fig. 2D), which may account for the hyperproliferative
phenotype in the lungs of KrasG12D;IkkαΔLu mice compared with
KrasG12D mice. Of note, decreased IKKα expression was seen in
some KrasG12D-lung ADCs and this was accompanied by re-
duced p53 and p21 expression (Fig. 2D). These results suggest
that reduced IKKα expression in lung ADCs is associated with
increased cell proliferation and decreased cell senescence.
To determine the epithelial cell-autonomous role of IKKα in
lung ADC development, we generated a KrasG12D ADC (Kras-
CL) cell line (Fig. 2E) and transplanted these cells into the lungs
of C57BL/6 WT mice. From the resulting lung ADCs, we iso-
lated another cell line, KrasIKKαL, that expressed less IKKα than
the parental Kras-CL cells (Fig. 2E and Fig. 2F, Top Left).
KrasIKKαL cells generated many more ADCs than the parental
Kras-CL cells after transplantation into C57BL/6 WT mice, al-
though both cell lines contained an activated KrasG12D allele
(Fig. 2F, Bottom Left and Right and Fig. S2D). To verify the
inhibitory effect of IKKα on tumorigenesis, we reexpressed IKKα
into KrasIKKαL cells and found that reintroduction of IKKα re-
duced tumor sizes compared with controls when these cells were
injected s.c. into nude mice (Fig. 2G and Fig. S2E). These results
indicate that reduced IKKα expression in lung ADC cells
promotes tumorigenesis.
IKKα Ablation Enhances ROS in Lung ADCs, and Treatment with
Apocynin Attenuates ROS and Lung Tumorigenesis. ROS induce
p53 expression (35). Unexpectedly, however, we detected more
ROS in KrasG12D;IkkαΔLu ADCs than in KrasG12D ADCs (Fig.
3A). Using gene expression array analysis (GSE84159), we found
increased expression of genes encoding the NADPH oxidase
(NOX) complex subunits that are involved in ROS generation
(36), such as Cyba, Ncf2, Ncf1, and Cybb, which encodes NOX2
(37), in KrasG12D;IkkαΔLu lungs compared with KrasG12D lungs
(Fig. 3B). We did not observe increased expression of other
NOX types. RT-PCR confirmed the significantly higher levels of
Nox2 in KrasG12D;IkkαΔLu lungs compared with KrasG12D lungs
(Fig. 3C). Moreover, IB analysis showed significantly higher
NOX2 levels in KrasG12D;IkkαΔLu ADCs compared with
KrasG12D ADCs (Fig. 3D and Fig. S3A). Indeed, some human
Fig. 2. IKKα deletion promotes cell growth but reduces cell senescence. (A) Lung appearance and weights of KrasG12D mice (n = 8) and KrasG12D;IkkαΔLu mice
(n = 7) and Ki67-stained bronchial epithelial cells in the lungs of these mice (n = 3 mice for 10 slides/group; Right) at 4 mo after Ad.Cre treatment. **P < 0.01;
***P < 0.001, Student’s t test. (B) Lung appearance and weight in four KrasG12D and three KrasG12D;IkkαKA/KA mice (Left and Center) and Ki67-stained
bronchial epithelial cells in the lungs of these mice (n = 3 mice/group; Right) at 4.5 mo after Ad.Cre treatment. **P < 0.01, Student’s t test. (C) Compari-
son of SA-β-gal staining intensities between KrasG12D;IkkαΔLu and KrasG12D tumors (n = 3 mice/group). SA, senescence-associated. **P < 0.01, Fisher’s exact test.
(D) IB analysis of IKKα, p53, and p21 expression in WT lungs and KrasG12D and KrasG12D;IkkαΔLu ADCs. β-actin served as a protein-loading control. (E) A scheme
for generating Kras-CL and KrasIKKαL cell lines involving intratracheal injections of these cells into WT mice with a C57BL/6 background. ADCs generated by
these cells are stained with H&E. (Scale bar: 25 μm.) (F) IB analysis of IKKα in Kras-CL and KrasIKKαL cells. β-actin served as a protein-loading control (Top Left).
Shown are lung appearance (Bottom Left) and tumor burden (Right) in WT mice receiving intratracheal injections of Kras-CL (n = 4) or KrasIKKαL (n = 5) cells
(5 × 106 cells/mouse), as analyzed statistically using Student’s t test. ***P < 0.001. (G) The growth of tumors in nude mice receiving s.c. injection of IKKα- or
control vector-transfected KrasIKKαL cells (n = 5 mice/group) for 2 wk. Data represent mean ± SD. **P < 0.01, Student’s t test.
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lung ADCs expressed reduced IKKα and increased NOX2 (Fig.
3E). Another analysis (1) showed a negative correlation between
NOX2 and IKKα expression in human lung ADCs (Fig. S3B),
suggesting the relevance of reduced IKKα and increased NOX2
in human lung ADC development.
To verify whether IKKα expression is inversely correlated with
ROS in lung ADC, we knocked down IKKα in human A549 lung
ADC cells, which carry a KrasG12S mutation (38), and in mouse
Kras-CL ADC cells. Down-regulation of IKKα increased ROS in
both A549 and Kras-CL cells, but treatment with apocynin, a
NOX inhibitor (36), or N-acetyl cysteine (NAC), an antioxidant
(29), decreased ROS accumulation in IKKα-deficient A549 and
Kras-CL cells (Fig. 3 F and G and Fig. S3 C and D). Oral ad-
ministration of apocynin, dissolved in drinking water containing
1.5% ethanol, for 4 mo significantly reduced the lung ADC
burden in KrasG12D;IkkαΔLu mice compared with vehicle-treated
KrasG12D;IkkαΔLu mice (Fig. 3H, Left); however, treatment with
apocynin did not decrease the lung ADC burden in KrasG12D
mice compared with controls (Fig. 3H, Right). These results
suggest that IKKα reduction results in increased amounts of
NOX2 and intratumoral ROS. IKKα is part of the IKK complex,
but knockdown of IKKα did not alter NF-κB activity in
A549 cells (Fig. S3E), suggesting that IKKα may regulate
NOX2 expression and ROS levels via an NF-κB–independent
mechanism.
Knockdown of NOX2 in Lung ADC Cells Inhibits Lung ADC Growth, and
IKKα Regulates NOX2 Expression via the Nox2 Promoter. To verify
the relationships among epithelial cell IKKα, NOX2, and ROS in
lung tumorigenesis, we confirmed higher ROS levels in
KrasIKKαL cells than in Kras-CL cells and verified that treatment
with apocynin reduced ROS levels in KrasIKKαL cells (Fig. 4 A
and B). Because Kras-CL cells required more than 3 mo to
generate lung ADCs in WT mice, we used KrasIKKαL cells to
determine the effect of NOX2 and ROS on ADC formation.
Consistently, a 6-wk course of treatment with apocynin reduced
KrasIKKαL cell–generated lung ADC numbers and lung weights
in C56BL/6 WT mice compared with controls (Fig. 4C). These
results demonstrate that IKKα levels in lung ADC cells are in-
versely correlated with ROS levels and lung tumor development
and that increased ROS enhance the tumorigenic potential of
KrasIKKαL cells.
Furthermore, KrasIKKαL cells expressed higher levels of Nox2
mRNA compared with Kras-CL cells (Fig. 4D), and silencing
IKKα resulted in elevated NOX2 expression in A549 cells (Fig.
S4 A and B). In contrast, knockdown of NOX2 significantly at-
tenuated ROS levels in KrasIKKαL cells and impaired KrasIKKαL
cell-generated lung tumors in C57BL/6 WT mice at 6 wk after
the transplantation of Nox2 Si-RNA– or control Si-RNA–treated
KrasIKKαL cells (Fig. 4 E and F), although NOX2 knockdown had
less effect on lung weight than apocynin, suggesting that in-
creased NOX2 expression enhances the tumorigenic potential of
KrasIKKαL cells by elevating ROS levels.
We then investigated the mechanism underlying the regulation
of NOX2 expression by IKKα. The aryl hydrocarbon receptor
(AhR) is known to repress Nox2 transcription (39). We postu-
lated that IKKαmay regulate Nox2 transcription via its effects on
AhR activity. Indeed, an interaction between IKKα and AhR was
detected by pull-down assays with an anti-AhR or an anti-IKKα
antibody in A549 cells (Fig. S4C). In addition, kinase-inactive
IKKα (IKKα-KA), but not a mutant IKKα with its LZ deletion
from amino acids 441–531 (IKKα-ΔLZ), interacted with AhR
(Fig. S4D), suggesting that IKKα may regulate Nox2 expression
independent of its kinase activity. Chromatin immunoprecipita-
tion (ChIP) assays demonstrated that both IKKα and AhR were
associated with the xenobiotic response element-containing re-
gion of the Nox2 promoter in Kras-CL cells and in human
A549 cells (Fig. 4G and Fig. S4 E and F). In contrast, IKKα
depletion decreased the recruitment of AhR to the Nox2 pro-
moter, and reintroduction of WT IKKα or IKKα-KA, but not of
IKKα-ΔLZ, recruited AhR to the Nox2 promoter in IKKα-
deficient Kras-CL and A549 cells (Fig. 4G and Fig. S4E, Left, and
Fig. S4F). Furthermore, silencing IKKα elevated Nox2 expression
in Kras-CL cells, while reintroducing IKKα or IKKα-KA, but not
IKKα-ΔLZ, elevated NOX2 expression in IKKα-deficient Kras-
CL cells (Fig. 4H and Fig. S4E, Right), although a slight reduction
in IKKα-KA binding to the Nox2 promoter was seen, suggesting
that IKKα integrity, but not its kinase activity, is required for the
regulation of NOX2 expression. These results indicate that IKKα
suppresses NOX2 expression by recruiting AhR to the Nox2
promoter, whereas IKKα deletion diminishes AhR binding to the
Nox2 promoter, leading to increased Nox2 expression and ROS
production (Fig. 4I).
Fig. 3. IKKα ablation increases NOX2 expression, and NOX inhibition re-
duces lung tumor burden. (A) Increased levels of ROS stained with IF (Left)
for 2′,7′-dichlorofluorescein diacetate (DCF-DA, in green) in tumors derived
from KrasG12D;IkkαΔLu mice compared with KrasG12D tumors and WT
lungs (Right). n = 6/group. ***P < 0.001, Student’s t test. (B) Comparison
of expression levels of genes encoding Cyba, Ncf2, Ncf1, and Cybb in
KrasG12D;IkkαΔLu lungs vs. WT (red) and in KrasG12D lungs vs. WT (green), as
determined by gene array analysis. Red asterisk: Cybb is also the name of the
Nox2 gene. (C) RT-PCR analysis of Nox2 mRNA expression in KrasG12D and
KrasG12D;IkkαΔLu lungs (n = 6). Data represent mean ± SEM (three repeats).
*P < 0.05, Student’s t test. (D) IB analysis of NOX2 expression in four KrasG12D
and five KrasG12D;IkkαΔLu lung ADCs (Fig. S3A). Data represent mean ± SD
(three repeats). *P < 0.05, Student’s t test. (E) IB analysis of IKKα, NOX2, and
NRF2 expression in human lung ADCs. Red asterisks indicate a relationship
between IKKα and NOX2. β-actin served as a protein-loading control. (F and
G) Apocynin (100 μM) or NAC (10 mM) reduces ROS (stained with DCF-DA)
induced by IKKα down-regulation in human A549 cells (F) and mouse Kras-
CL cells (G). (H) The effect of apocynin on lung tumor burden in KrasG12D
(Right) and KrasG12D;IkkαΔLu (Left) mice. n = 6 for untreated mice; n = 9 for
treated mice). *P < 0.05, Student’s t test. n.s., not significant.
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KrasG12D;IkkαΔLu ADCs Express Reduced NRF2, and NAC Treatment
Inhibits Lung ADC Burden in KrasG12D;IkkαΔLu Mice. A feedback
loop between ROS production and elimination balances physi-
ological ROS amounts. We expected to find that increased ROS
resulted in NRF2 activation. Surprisingly, however, the expres-
sion of NRF2 target genes encoding antioxidants and detoxifying
enzymes was lower in KrasG12D;IkkαΔLu lungs than in KrasG12D
lungs (Fig. S5A). IB analysis showed that KrasG12D ADCs
expressed more NRF2 than WT lungs, whereas KrasG12D;
IkkαΔLu ADCs expressed less NRF2 than WT lungs (Fig. 5A).
Among KrasG12D ADCs, those expressing less IKKα consistently
showed lower NRF2 and p21 expression (Fig. 5B). Importantly,
IB analysis showed reduced IKKα and NRF2 expression in a
subfraction of human lung ADCs, and indeed, some human lung
ADCs showed reduced IKKα and NRF2 expression and increased
NOX2 expression (Fig. 3E and Fig. S5B). Moreover, using RT-
PCR, we examined additional 47 human lung ADCs (stage II–IV)
and found that a subgroup of these ADCs expressed significantly
less IKKα and NRF2 compared with another ADC group (Fig.
5C), suggesting clinical relevance of the reduced IKKα and
NRF2 expression in human lung ADC.
If reduced NRF2 expression promotes ROS accumula-
tion, which further contributes to increased tumorigenesis, then
treatment with NAC should inhibit lung ADC burden in
KrasG12D;IkkαΔLu mice. Indeed, NAC treatment significantly
decreased lung weights and ADC burden in KrasG12D;IkkαΔLu
mice compared with controls, but this treatment did not signif-
icantly affect the ADC burden in KrasG12D mice (Fig. 5 D and E).
The oxidative DNA damage (8-OHdG) marker was higher in
KrasG12D;IkkαΔLu ADCs than in KrasG12D ADCs, and NAC
treatment decreased DNA damage (Fig. 5F), suggesting that
accumulated ROS cause more DNA damage, which is associated
with enhanced lung tumorigenesis. As expected, the expression
levels of NRF2 targets Nqo1 and Gpx2 were significantly lower
in KrasG12D;IkkαΔLu ADCs than in KrasG12D ADCs (Fig. 5G),
suggesting that ROS scavengers regulate lung ADC development
in the absence of IKKα.
IKKα Loss Down-Regulates NRF2 Expression in an Epigenetic Manner.
Treatment with NAC decreased the number of ROS in
KrasIKKαL cells and also inhibited KrasIKKαL cell-generated lung
tumor growth in WT mice compared with controls (Fig. 6 A and
B), suggesting a reciprocal correlation between IKKα-regulated
NRF2 expression and ROS levels during lung tumorigenesis.
KEAP1 is a major negative regulator of NRF2 stability (40).
Kras-CL and KrasIKKαL cells expressed similar amounts of
Fig. 4. IKKα represses expression of Nox2 through
regulation of AhR activity. (A, Left) DCF-DA staining
for ROS in Kras-CL (Kras) and KrasIKKαL (KrasIKKαlow)
cells using flow cytometry. (A, Right) Relative DCF
levels in the two cell lines (n = 4/group). Data rep-
resent mean ± SD (three repeats). ***P < 0.001,
Student’s t test. (B) Treatment with apocynin (100 μM)
reduces ROS in KrasIKKαL cells (n = 3/group). Data
represent mean ± SD (three repeats). ***P < 0.001,
Student’s t test. (C) Treatment with apocynin inhibits
KrasIKKαL cell-derived lung ADCs and reduces lung
size in WT mice compared with the untreated con-
trol group. Experimental mice, n = 5; control mice,
n = 6. *P < 0.05; **P < 0.01, Student’s t test. (D) RT-
PCR analysis of Nox2 mRNA expression in Kras-CL
and KrasIKKαL cells (n = 3). Data represent mean ±
SD (three repeats). ***P < 0.001, Student’s t test.
(E) DCF-DA levels of KrasIKKαL cells treated with Si-
control (control) or Si-Nox2. n = 3/group. Data rep-
resent mean ± SD (three repeats). ***P < 0.001,
Student’s t test. (F) Tumor appearance (Left) and
numbers (Right) generated by KrasIKKαL cell receiving
Si-control and Si-Nox2 RNA in the lungs of WT mice.
n = 5 for controls; n = 6 for Si-Nox2). Data represent
mean ± SD **P < 0.01; Student’s t test. (G) ChIP
analyses for IKKα and AhR binding to Nox2 promoter
using antibody against AhR (Left) or IKKα (Right) for
IP, followed by PCR with Nox2 promoter primers in
Kras-CL cells (Si-Cont, control) or Kras-CL cells si-
lencing IKKα or overexpressing WT IKKα, IKKα mu-
tant lacking its LZ motif (IKKα-ΔLZ), and IKKα-KA
(kinase inactivation). Si-Cont, Si-control RNA; Si-IKKα,
Si-IKKα RNA. Data represent mean ± SD (three re-
peats). *P < 0.05; ***P < 0.001, Student’s t test. n.s.,
not significant. (H) Knockdown of IKKα (Si-IKKα) or
reintroduction of WT IKKα, IKKα-ΔLZ, and IKKα-KA
regulates Nox2 expression in Kras-CL cells, as ana-
lyzed by RT-PCR. Data represent mean ± SD (three
repeats). ***P < 0.001; **P < 0.01, Student’s t test.
n.s., not significant. (I) A working model for regula-
tion of Nox2 expression by IKKα through AhR. XRE,
xenobiotic response element, a DNA-binding site for
AhR on the Nox2 promoter. IKKα deletion reduces
AhR binding to the Nox2 promoter, enhancing Nox2
promoter activity and lung tumor development.
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KEAP1, however (Fig. S6A). Expression of Nrf2 mRNA was
lower in KrasG12D;IkkαΔLu lungs than in KrasG12D lungs (Fig. 6C).
Knockdown of IKKα attenuated NRF2 expression, and reintro-
duction of IKKα rescued NRF2 expression (Fig. S6B), suggesting
that IKKα regulates Nrf2 gene transcription.
Trimethylation at lysine 9 of histone H3 (H3-K9) represses
gene expression by recruiting DNA methyltransferases, and tri-
methyltransferase Suv39h1 is required for H3-K9 trimethylation
(13, 41, 42). We previously reported that IKKα interacts directly
with H3 protein, which in turn shields chromatin-associated
H3 from H3-K9 trimethylation by preventing Suv39h1 from
accessing the Stratifin chromatin (13). Several CpG islands are
present in the Nrf2 promoter region. Nrf2 mRNA levels were
significantly lower in KrasIKKαL cells than in Kras-CL cells (Fig.
6D). Treatment with 5-azacytidine, a DNA methyltransferase
inhibitor, increased Nrf2 mRNA levels in KrasIKKαL cells (Fig.
6E), suggesting that IKKα modulates the Nrf2 promoter activity
in an epigenetic manner.
Using ChIP assays, we found IKKα to be associated with the
Nrf2 promoter in Kras-CL cells (Fig. 6F and Fig. S6C). With the
loss of IKKα from the Nrf2 promoter in KrasIKKαL cells, in-
creased levels of trimethylated-H3-K9, Suv39h1, and Dnmt3a
were found at the Nrf2 promoter compared with Kras-CL cells
(Fig. 6F and Fig. S6C). Reintroducing WT IKKα or IKKα-KA, but
not IKKα-ΔLZ, formed the complex with Nrf2 promoter in
KrasIKKαL cells (Fig. S6D). Consistently, silencing IKKα decreased
Nrf2 expression in Kras-CL cells, and reintroducing WT IKKα or
IKKα-KA, but not IKKα-ΔLZ, increased Nrf2 expression in
IKKα-deficient Kras-CL cells (Fig. 6G). These results suggest that
IKKα suppresses H3-K9 trimethylation on the Nrf2 promoter,
thereby increasing its transcription. In contrast, IKKα loss elevates
H3-K9 trimethylation on the Nrf2 promoter, inhibiting NRF2
expression (Fig. 6H and Fig. S6E).
To elucidate how IKKα expression is down-regulated in
KrasIKKαL cells, we sequenced full-length IKKα cDNA and
identified a missense mutation at nucleotide 2054 (amino acid 685)
in KrasIKKαL cells, Kras-CL cells, and KrasG12D-induced ADCs (Fig.
Fig. 5. IKKα ablation reduces NRF2 expression, and inhibition of ROS de-
creases lung tumorigenesis. (A) IB analysis of NRF2 expression in WT lungs
and KrasG12D and KrasG12D;IkkαΔLu ADCs. β-actin served as a protein-loading
control. The same protein membrane was used as shown in Fig. 2D. (B) IB
analysis of expression of IKKα, NRF2, and p21 in KrasG12D ADCs. Based on
expression levels of IKKα, these ADCs were divided into two groups: low
group (n = 5) and high group (n = 9). NRF2 and p21 levels were further
compared between the two ADC groups and then statistically analyzed us-
ing Student’s t test. *P < 0.05. (C) RT-PCR analysis of expression levels of
IKKα/CHUK and NRF2 in 47 human lung ADCs. These ADCs were divided into
two groups (n = 21 and n = 26) based on IKKα levels. Gapdh levels were used
to normalize IKKα and NRF2 expression. ***P < 0.001; ****P < 0.0001,
Student’s t test. (D) Lung weight and appearance in KrasG12D;IkkαΔLu mice
treated with (n = 5) or without (n = 4) NAC, statistically analyzed by Stu-
dent’s t test. *P < 0.05. (E) Tumor burden in KrasG12D mice (Left) treated with
(n = 4) or without (n = 4) NAC and KrasG12D;IkkαΔLu mice (Right) treated with
(n = 5) or without (n = 4) NAC. Data were statistically analyzed by Student’s
t test. n.s., not significant. ***P < 0.001. (F) Oxidative DNA damage indicated
by IF staining with 8-hydroxy-2′-deoxyguanosine (8-OHdG) in WT lungs and
ADCs of KrasG12D, KrasG12D;IkkαΔLu, and NAC-treated KrasG12D;IkkαΔLu mice
(n = 5). (Scale bar: 25 μm.) (G) RT-PCR analysis of Nqo1 and Gpx2 mRNA in
KrasG12D (n = 3) and KrasG12D;IkkαΔLu (n = 4) lung ADCs. Data were statisti-
cally analyzed by Student’s t test. **P < 0.01; ***P < 0.001.
Fig. 6. IKKα regulates NRF2 expression in an epigenetic manner.
(A) Treatment with NAC (10 mM) inhibits DCF (ROS) levels in KrasIKKαL cells
(n = 3/group). Data represent mean ± SD (three repeats). ***P < 0.001,
Student’s t test. (B) Treatment with NAC (10 g/L) inhibits the development of
lung tumors generated by KrasIKKαL cells in WT mice. Control mice, n = 4;
NAC-treated mice, n = 5. Data represent mean ± SD. **P < 0.01, Student’s
t test. (C) RT-PCR analysis of Nrf2 mRNA levels in four WT, six KrasG12D, and
10 KrasG12D;IkkαΔLu lungs. Data are analyzed by Student’s t test. *P < 0.05;
***P < 0.001. (D) RT-PCR analysis of Nrf2 mRNA in Kras-CL and KrasIKKαL cells
(n = 3/group). Data represent mean ± SD (three repeats). **P < 0.01, Stu-
dent’s t test. (E) RT-PCR analysis of Nrf2 mRNA expression in KrasIKKαL cells
following treatment with 5-azacytidine (5-Aza). Data represent mean ± SD
(three repeats). **P < 0.01, Student’s t test. n.s., not significant. (F) ChIP
analyses for binding of IKKα, trimethylated-H3K9 (H3K9me3), Suv39h1, or
Dnmt3a to Nrf2 promoter using antibodies against these proteins for im-
munoprecipitation, followed by PCR with Nrf2 promoter (-P) primers. Data
represent mean ± SD (three repeats). *P < 0.05; **P < 0.01; ***P < 0.001,
Student’s t test. (G) Knockdown of IKKα (Si-IKKα) or reintroduction of WT
IKKα, IKKα-ΔLZ, and IKKα-KA regulates Nrf2 expression in Kras-CL cells, as
analyzed by RT-PCR. Data represent mean ± SD (three repeats). ***P < 0.001;
**P < 0.01, Student’s t test. n.s., not significant. (H) A working model for
NRF2 regulation and the pathways in IKKα+KrasG12D and IKKα−KrasG12D ADC
cells. Blue circle, trimethylation; white circle, no trimethylation; S39h1,
Suv39h1; H3, histone H3; arrow, promotion; cross lines, inhibition; dashed
line, no response; dashed arrow, discussed in Fig. 7.
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S6F). Interestingly, KrasIKKαL cells exhibited many additional Ikkα
mutations surrounding the nucleotide 2054 genetic lesion, suggest-
ing that these mutations confer a growth advantage, possibly by
destabilizing the IKKα protein. Accordingly, IKKα immunopre-
cipitation fromKras-CL and KrasIKKαL cells, followed by IB analysis
with an anti-ubiquitin antibody, showed more ubiquitinated IKKα
in KrasIKKαL cells compared with Kras-CL cells (Fig. S6G, Top).
Treatment with MG132, a proteasome inhibitor, elevated IKKα
and NRF2 levels in KrasIKKαL cells (Fig. S6G, Bottom), suggesting
that tumor-associated mutations promote proteasomal degradation
of IKKα. We previously detected the same Ikkα mutations and
deletions in the C-terminal region of IKKα in skin SCCs derived
from carcinogen-treated Ikkα+/− and WT mice (13, 15, 26). These
mutations impaired the IKKα activity that controls the G2/M cell
cycle checkpoint in response to DNA damage and keratinocyte
growth. Thus, the DNA encoding the IKKα C-terminal region be-
haves like a mutational “hot spot” in different types of cancers.
A ROS-Mediated NRF2-NQO1 Pathway Leads to the Induction of p53/
p21 and Cell Senescence, and IKKα Inactivation Reverses This
Pathway. Reduction of NQO1, an NRF2 target, results in
p53 degradation independent of MDM2 (43, 44), suggesting that
along with antioxidative activity, the ROS-mediated NRF2-
NQO1 pathway may prevent tumor progression by up-regulating
p53, p21, and cell senescence (30). We hypothesized that re-
duced IKKα down-regulates NRF2 and NQO1 expression, which
attenuates p53 and p21 expression and cell senescence. Indeed,
KrasIKKαL cells expressed reduced IKKα, NRF2, NQO1, p53,
and p21 and showed attenuated cell senescence compared with
Kras-CL cells (Fig. 7 A, Left and B). Silencing of IKKα repressed
NRF2, NQO1, p53, and p21 expression and attenuated cell se-
nescence in Kras-CL and A549 cells (Fig. 7 A, Center and C and
Fig. S7 A and B). In addition, silencing of NRF2 or NQO1 re-
pressed NQO1, p53, and p21 expression and attenuated cell
senescence in Kras-CL cells (Fig. 7 A, Right, D and E and Fig.
S7C). These results suggest that IKKα reduction blocks cell cycle
arrest by decreasing NRF2, NQO1, and p21 expression. Impor-
tantly, silencing of IKKα, NRF2, or NQO1 in Kras-CL cells
promoted tumor growth compared with the control when these
cells were injected s.c. into nude mice (Fig. 7 F–H).
To demonstrate links among IKKα action, ROS, and ROS-
mediated cell senescence, we examined the effect of NAC and
apocynin on cell senescence (p53/p21) in KrasIKKαL and Kras-CL
cells (Fig. 7I). Indeed, treatment with NAC or apocynin induced
p53/p21 expression in KrasIKKαL cells. This induction was stronger
in KrasIKKαL cells than in Kras-CL cells (Fig. 7I). Taken together,
these findings show that IKKα ablation not only elevates
NOX2 expression, but also blocks the induction of NRF2 and
NQO1, resulting in accumulated ROS and attenuated cell senes-
cence, both of which promote lung tumor development (Fig. 7J).
Furthermore, we examined NF-κB activity in Kras-CL and
KrasIKKαL cells following TNFα treatment, and found that NF-
κB activity was not decreased in KrasIKKαL cells compared with
Kras-CL cells (Fig. S7D). However, relative to Kras-CL,
KrasIKKαL cells showed increased expression of the regulators
for stem cell properties, mitogenic activity, and inflammation
and reduced expression of the regulators for apoptosis and an-
tioxidant/detoxification functions, as analyzed by a microarray
assay (GSE84163; Fig. S7E). Among these alterations, IKKα
down-regulates Fgf13, Adam12, and Egfr (14, 15) and ROS el-
evate Jak2, Egfr, and Notch1 expression (45–47). These changes
may also contribute to the enhanced tumorigenic potential of
KrasIKKαL cells compared with Kras-CL cells.
Discussion
Here we demonstrate that lung-specific IKKα deletion promotes
KrasG12D-mediated lung ADC development in association with
elevated NOX2, down-regulated NRF2, accumulated ROS, and
attenuated cell senescence. Pharmacologic inhibition of NOX or
ROS attenuates lung ADC development in KrasG12D;IkkαΔLU
mice. These results define a previously undescribed role of
IKKα, in which dual IKKα-NOX2 and IKKα-NRF2 pathways
control ROS homeostasis and proliferation/survival that regu-
late KrasG12D-mediated lung ADC growth. Importantly, a frac-
tion of human lung ADCs harbor CHUK locus mutations and
deletions or express reduced IKKα, some of which coexpress
activated KRAS. During malignancy development, the activa-
tion of oncogenes is a ubiquitous phenomenon. Human lung
ADCs express different oncogenes that induce mitogenic stress
and ROS (29). Therefore, the mechanism identified in this study
may apply in those CHUK-deficient human ADCs that do not
carry KRAS alterations. Furthermore, KRAS mutations fre-
quently occur in human pancreatic and colon cancers (cBioPortal).
CHUK mutations and hemizygous deletions are also found
in these patients, suggesting that IKKα inactivation or re-
duction may promote KRAS mutation-involved pancreatic and
colon cancer development through a mechanism provided in
this study.
FVB L-IkkαKA/KA mice develop spontaneous lung SCCs, in
which no activating Kras mutations are detected, but not ADCs
(5). L-IkkαKA/KA mice develop systemic inflammation, marked
pulmonary macrophage infiltration, and reduced epithelial cell
IKKα levels before lung SCC formation. Restoration of IKKα in
K5-expressing lung epithelial cells or depleting macrophages
prevents lung SCC development. In this study, we detected lung
ADCs, but not SCCs, in KrasG12D, IkkαΔLU, and KrasG12D;
IkkαΔLUmice. These mice have a WT background before Ad.Cre
treatment. Furthermore, KrasG12D;IkkαKA/KA mice only de-
veloped lung ADCs. Notably, activating KRAS mutations are
detected in ∼35% and 5% of human lung ADCs and SCCs, re-
spectively (1, 2), suggesting that activated Kras may pre-
dominantly induce ADCs in the lung, and that inflammatory
conditions may also determine the formation of lung cancer,
either ADC or SCC (4). The detailed mechanism remains to
be revealed. Moreover, lung-specific Ikkα ablation induced
spontaneous lung ADCs. Reintroduction of IKKα inhibited
KrasIKKαL cell-generated tumor growth, and silencing of IKKα
promoted Kras-CL cell-generated tumor growth. Hence, the
epithelial-intrinsic IKKα is critical for suppressing lung ADC
development.
Down-regulation of NF-κB can cause apoptosis of KrasG12D
ADC cells expressing reduced p53 (17, 18). Here, we showed that
KrasG12D;IkkαΔLU and KrasG12D ADCs expressed comparable
amounts of nuclear NF-κB proteins, although p53 expression was
lower in KrasG12D;IkkαΔLU ADCs than in KasG12D ADCs, sug-
gesting that a basal NF-κB activity is sufficient for maintaining
tumor cell survival. Furthermore, KrasG12D;IkkαΔLU ADCs
showed increased proliferating cells and reduced p53/p21/senes-
cence. NQO1 has been shown to stabilize the p53 protein in-
dependent of MDM2, while reduced NQO1 destabilizes p53 (43,
44). We found that IKKα deletion decreased expression of
NRF2 and NQO1, which led to reduced p53/p21 and cell senes-
cence in lung cancer cells, suggesting that IKKα is required to
maintain NRF2, NQO1, and p53/p21 pathways for establishment
of a barrier that antagonizes tumor progression.
On the other hand, silencing of IKKα was found to down-
regulate NRF2 and NQO1 expression, resulting in reduced p53/
p21 expression and cell senescence. Therefore, a reduction in IKKα
changes the antitumorigenic effect of Kras-induced ROS to a
protumorigenic effect that enhances Kras-induced ADC progres-
sion. Although it has been reported that NRF2 deletion alone
promotes the KrasG12D-mediated early ADCs and inhibits the ad-
vanced KrasG12D-mediated ADCs (23, 48), in this study, along with
reduced NRF2, IKKα deletion also promoted NOX2 expression,
leading to further ROS accumulation and oxidative damage. Most
likely, the ROS scavenging system induced by NRF2 becomes more
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Fig. 7. An antagonizing relationship between accumulating ROS pathways and senescence. (A) IB analysis of IKKα, NRF2, NQO1, p53, p21, andMDM2 expression in Kras-CL
and KrasIKKαL cells (Left), as well as Kras-CL cells treated with Si-Control, Si-IKKα (Center), or Si-NQO1 (Right). β-actin served as a protein-loading control. (B) SA-β-gal–positive
cells in Kras-CL and KrasIKKαL cells (n= 3/group). Data representmean± SD (three repeats). ***P< 0.001, Student’s t test. (C) The effect of IKKα knockdown on SA-β-gal levels
in Kras-CL cells (Left) and A459 cells (Right) (n= 3/group). Data representmean ± SD (three repeats). ***P< 0.001, Student’s t test. (D) The effect of NRF2 knockdown on SA-
β-gal levels in Kras-CL cells (n = 3/group). Data represent mean ± SD (three repeats). ***P < 0.001, Student’s t test. (E) The effect of NQO1 knockdown on SA-β-gal levels in
Kras-CL cells (n = 3/group). Data represent mean ± SD (three repeats). ***P < 0.001, Student’s t test. (F) Appearance (Left) and weight (Right) of tumors in nude mice
receiving s.c. injections of Si-control or Si-IKKα–transfected Kras-CL cells for 3 wk (n = 10 tumors from 5 mice/group). Data represent mean ± SD. **P < 0.01, Student’s t test.
(G) Appearance (Left) and weight (Right) of tumors in nude mice receiving s.c. injections of Si-control or Si-NRF2–transfected Kras-CL cells for 3 wk (n = 10 tumors from
5mice/group). Data representmean± SD. **P< 0.01, Student’s t test. (H) Appearance (Top) andweight (Bottom) of tumors in nudemice receiving s.c. injections of Si-control
or Si-NQO1 transfected Kras-CL cells for 3wk (n= 9 tumors from 5mice/group). Data representmean± SD. *P< 0.05, Student’s t test. (I) IB analysis of p53 and p21 expression
in Kras-CL and KrasIKKαL cells treated with NAC or apocynin (Apocy). Cont, untreated cells. β-actin served as a protein-loading control. (J) A working model for regulation of
NOX2 or NRF2, their pathways, and biological consequences, regulated by IKKα in IKKα+KrasG12D and IKKα−KrasG12D ADC cells. Blue circle, trimethylation; white circle, no
trimethylation; S39h1, Suv39h1; H3, histone H3; arrow, promotion or forward/maintaining; cross lines, inhibition; dashed line, no response.
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crucial for reducing oxidative damage in KrasG12D;IkkαΔLU mice
than in KrasG12Dmice. Overall, IKKα provides a protective role that
suppresses excessive ROS and also ensures a pathway for ROS-
induced antitumorigenic activity, thereby preventing ADC initia-
tion and progression.
Materials and Methods
All mice used in this study were cared for in accordance with the guidelines of
the Institutional Animal Care and Use Committee (IACUC) of the National
Institutes of Health. All animal experiments (protocols 14–051 and 14–052)
were approved by the IACUC. Ikkαf/f, IkkαKA/KA, and Ikkα+/− mice (12, 13, 15)
and KrasG12D mice (stock no. 008179; The Jackson Laboratory) were on a
C57BL/6 background. Athymic nude mice were obtained from Charles River
Laboratories [BALB/c; Crl:NU(NCr)-Foxn1nu]. Human lung adenocarcinomas
were obtained from Dr. David Schrump, Thoracic and Gastrointestinal On-
cology Branch, National Cancer Institute and from Sun Yat-Sen University
Cancer Center, Guangzhou, China. All human samples used in this study
were approved by the National Institutes of Health Internal Review Board
(protocol 06-C-0014) and by the Ethics Committee and Institutional Review
Board of Sun Yat-Sen University Cancer Center (YB2017-023), and informed
consent was been obtained from all patients.
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